<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
PRQR
ProQR Therapeutics
$
()


  • ProQR Therapeutics price target raised by 50c at Chardan, here's why

    3/14/2024 - 04:16am
  • ProQR Therapeutics sees cash runway into mid-2026

    3/13/2024 - 07:05am
  • ProQR Therapeutics reports 2023 EPS (EUR 0.35) vs. (EUR 0.90) last year

    3/13/2024 - 07:05am
  • ProQR Therapeutics announces Japanese Axiomer patent upheld

    2/15/2024 - 07:11am
  • Biotech Alert: Searches spiking for these stocks today

    1/19/2024 - 11:24am
  • ProQR highlights key updates from presentation of Axiomer RNA platform

    1/19/2024 - 07:01am
  • ProQR Therapeutics, RSRT join forces with Axiomer RNA editing collaboration

    1/5/2024 - 07:03am
  • ProQR completes divestment of late stage ophthalmic assets to Laboratoires Thea

    12/8/2023 - 07:33am
  • ProQR Therapeutics upgraded to Buy from Neutral at Chardan

    11/8/2023 - 05:04am
  • ProQR Therapeutics reports Q3 EPS (EUR 0.07) vs (EUR 0.33) last year

    11/7/2023 - 07:12am
  • ProQR Therapeutics announces strengthened IP with new U.S. patent

    11/6/2023 - 07:23am
  • ProQR Therapeutics announces termination of deal to sell ophthalmic assets

    9/27/2023 - 07:04am
  • ProQR Therapeutics price target lowered to $1.80 from $2.10 at Citi

    9/18/2023 - 06:47am
  • ProQR Therapeutics announces anticipated upcoming events

    8/3/2023 - 07:13am
  • ProQR Therapeutics reports Q2 EPS (EUR 0.10c) vs (EUR 0.19) last year

    8/3/2023 - 07:13am
dynamic_feed Breaking News